drugset / Trial / NCT07105059
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Phase 1
Recruiting
18 enrolled
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb · collabJohnson & Johnson · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).
Timeline
- Start
- 2025-08-08
- Primary completion
- 2028-08-08
- Completion
- 2028-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mezigdomide | Small molecule | — | — |
| Subject | Teclistamab | Monoclonal antibody | — | — |